PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Pacific Biosciences of California, Inc. (PACB)
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacificbiosciences.com
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. “We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications,” said Christian Henry, President and CEO of PacBio. “In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Looking ahead, we believe that increased real-world evidence in the clinic, combined with the significantly lower costs enabled by SPRQ-Nx, will catalyze our next phase of growth in 2026 and beyond.” Fourth quarter and full year results: Q4 2025(Preliminary, unaudited)Q4 20242025(Preliminary, unaudi
Show less
Read more
Impact Snapshot
Event Time:
PACB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PACB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PACB alerts
High impacting Pacific Biosciences of California, Inc. news events
Weekly update
A roundup of the hottest topics
PACB
News
- PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases [Yahoo! Finance]Yahoo! Finance
- Pacific Biosciences of California reports prelim Q4, FY revenue above estimate [Seeking Alpha]Seeking Alpha
- PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic DiseasesGlobeNewswire
- PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)GlobeNewswire
- How PacBio (PACB) Is Seeing Its Fair Value Story Shift After ARK's Share Purchase [Yahoo! Finance]Yahoo! Finance
PACB
Earnings
- 11/5/25 - Beat
PACB
Sec Filings
- 1/12/26 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- PACB's page on the SEC website